Physician profile
Michael Rose
NPI 1679144810
$2,387.96
in general payments reported to CMS, 2019-2025
22 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $384 · 2023: $764 · 2024: $427 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,669.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $486.71 | 2021-2025 | Prostep, Variax, Augment Injectable |
| Integra Lifesciences Corporation | $440.97 | 2022-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Treace Medical Concepts, INC. | $195.29 | 2023-2024 | |
| Bioventus LLC | $162.66 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $156.53 | 2022-2025 | Grafix Pl, Vlp Foot, Evos |
| Paragon 28, INC. | $136.05 | 2023 | Portfolio |
| Angiodynamics, INC. | $126.75 | 2021 | |
| Avita Medical Americas, LLC | $123.35 | 2024 | |
| Vilex LLC | $96.82 | 2023 | |
| Kci USA, INC. | $72.29 | 2021 | |
| Organogenesis INC. | $70.05 | 2025 | Puraply Wound Matrix |
| Aroa Biosurgery Incorporated | $62.58 | 2022-2024 | |
| Surgenex LLC | $47.69 | 2025 | Surgraft, Ardeograft, Pellograft |
| Paratek Pharmaceuticals, INC. | $32.92 | 2022 | |
| Arteriocyte Medical Systems, INC. | $29.16 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $26.98 | 2021 | |
| Mimedx Group, INC. | $25.64 | 2025 | |
| Convatec INC. | $23.11 | 2025 | |
| Averitas Pharma INC. | $20.73 | 2023 | Qutenza |
| Sobi, INC | $18.80 | 2022 | |
| Nevro Corp. | $16.70 | 2024 | Senza |
| Heron Therapeutics, INC. | $16.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.